



# Financial Results for the 1st quarter of the year ending March 31, 2022

August 5, 2021

1. Financial Results for the 1st quarter of the year ending March 31, 2022
2. Forecast for the year ending March 31, 2022
3. Sustainability

# Summary for the 1st quarter of the year ending March 31, 2022



## Actual

- Revenue : **¥132.2B**
- Operating profit : **¥19.9B**  
(Positive in 4 segments including Imaging Products and Precision Equipment Business)
- Profit attributable to owners of the parent : **¥15.8B**

## YoY

- Revenue : **Up ¥67.5B**
- Operating profit : **Up ¥40.4B**
- Profit attributable to owners of the parent : **Up ¥29.3B**
- Increase in revenue in all segments
  - **Imaging Products Business** : Increase **¥24.9B** in revenue and **¥17.5B** in profit.  
Significant recovery in sales unit of digital cameras
  - **Precision Equipment Business** : Increase **¥32.2B** in revenue and **¥16.3B** in profit  
Mainly increased sales unit of FPD lithography systems

Note: Amounts in this statement are rounded down to the hundred millions of yen.

# 1st quarter of the year ending March 31, 2022: Financial Highlights



		FY2021/3 Q1 Actual (A)	FY2022/3 Q1 Forecast (B)	Change (B)-(A)	FY2020/3 Q1 Actual (reference)
Billions of yen					
<b>Revenue</b>		64.7	<b>132.2</b>	+67.5	142.9
<b>Operating Profit</b>		-20.5	<b>19.9</b>	+40.4	9.3
% vs Revenue		-31.7%	<b>15.1%</b>		6.5%
<b>Profit before income taxes</b>		-19.2	<b>21.1</b>	+40.3	10.7
% vs Revenue		-29.7%	<b>16.0%</b>		7.5%
<b>Profit attributable to owners of the parent</b>		-13.5	<b>15.8</b>	+29.3	8.2
% vs Revenue		-20.9%	<b>12.0%</b>		5.7%
<b>FCF</b>		-18.2	<b>-2.8</b>	+15.4	-0.7
Exchange Rate:	US \$	¥108	<b>¥110</b>	Impact on Revenue +4.9	¥110
	EURO	¥119	<b>¥132</b>	Impact on Operating Profit +1.7	¥124

Forecast for ¥20.0B of operating profit and ¥16.0B of profit attributable to owners of the parent were almost achieved in Q1. Revenue decreased but each profit increased compared to in FY2020/3 Q1.

# 1st quarter of the year ending March 31, 2022: Financial Highlights by Segment



Billions of yen		FY2021/3 Q1 Actual(A)	FY2022/3 Q1 Actual (B)	Change (B)-(A)
<b>Imaging Products Business</b>	Revenue	25.1	<b>50.0</b>	+99%
	Operating Profit	-8.3	<b>9.2</b>	¥17.5B
<b>Precision Equipment Business</b>	Revenue	19.6	<b>51.8</b>	+164%
	Operating Profit	-5.7	<b>10.6</b>	¥16.3B
<b>Healthcare Business</b>	Revenue	10.3	<b>15.8</b>	+53%
	Operating Profit	-2.4	<b>0.4</b>	¥2.8B
<b>Components Business</b>	Revenue	4.6	<b>7.7</b>	+67%
	Operating Profit	-0.3	<b>2.1</b>	¥2.4B
<b>Industrial Metrology and Others</b>	Revenue	4.9	<b>6.7</b>	+37%
	Operating Profit	0.9	<b>-1.0</b>	-¥1.9B
Corporate P/L non-attributable to any reportable segments	Revenue	—	—	—
	Operating Profit	-4.6	<b>-1.5</b>	¥3.1B
<b>Consolidated</b>	Revenue	64.7	<b>132.2</b>	+104%
	Operating Profit	-20.5	<b>19.9</b>	¥40.4B

Revenue improved in all segments. Operating profit improved excluding Industrial Metrology and others and recorded a surplus in 4 segments.

Note : In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.

# 1st quarter of the year ending March 31, 2022: Imaging Products Business



Billions of yen	FY2021/3 Q1 Actual (A)	FY2022/3 Q1 Actual (B)	Change (B)-(A)
<b>Revenue</b>	<b>25.1</b>	<b>50.0</b>	<b>+24.9</b>
<b>Operating Profit</b> % vs Revenue	<b>-8.3</b> -33.1%	<b>9.2</b> 18.4%	<b>+17.5</b>
<b>Digital Camera- Interchangeable Lens type</b> (Units sold: 1,000)	<b>140</b>	<b>220</b>	<b>+80</b>
<b>Interchangeable Lens</b> (Units sold: 1,000)	<b>220</b>	<b>390</b>	<b>+170</b>
<b>Compact DSC</b> (Units sold: 1,000)	<b>50</b>	<b>70</b>	<b>+20</b>

## Q1 YoY : Increased revenue and operating profit

- Mirrorless and high-priced interchangeable lenses have enjoyed strong sales on recovery in demand for cameras.
- Higher ASP on further progress in shift to models for pro/hobbyists. Revenues nearly doubled, due in part to the weaker yen.
- Q1 operating profit improved significantly YoY due to subdued sales expenses and deferred partial expenses to Q2 and beyond.

Note : In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.

# 1st quarter of the year ending March 31, 2022: Precision Equipment Business



Billions of yen	FY2021/3 Q1 Actual (A)	FY2022/3 Q1 Actual (B)	Change (B)-(A)
Revenue	19.6	51.8	+32.2
Operating Profit % vs Revenue	-5.7 -29.1%	10.6 20.5%	+16.3
FPD Lithography Systems (units)	0	13	+13
Semiconductor Lithography Systems New/Refurbished (units)	2/1	0/1	-2/±0

## Q1 YoY : Increased revenue and operating profit

- FPD Lithography Business: No system sales was booked in Q1 of the previous fiscal year due to the impact of COVID-19 and 13 unites were done in Q1 of this fiscal year. As installations have progressed well in this fiscal year, revenues and operating profits were increased.
- Semiconductor Lithography Business: Operation profit increase due to revenue contributions from the service business, etc. However, as the completion of some system installations were pushed out into Q2 and beyond, no new system sales was booked in Q1.

Note : In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.

# 1st quarter of the year ending March 31, 2022: Healthcare Business



Billions of yen	FY2021/3 Q1 Actual (A)	FY2022/3 Q1 Actual (B)	Change (B)-(A)
Revenue	10.3	15.8	+5.5
Operating Profit % vs Revenue	-2.4 -23.3%	0.4 2.5%	+2.8

## Q1 YoY : Increased revenue and operating profit

- Revenue and operating profits increased in both biological microscopes and retinal diagnostic imaging systems from the previous year impacted by COVID-19.
- Sales of biological microscopes increased mainly in the American market, and sales of retinal diagnostic imaging systems increased in response to the recovery of the mainstay US and European markets.



# 1st quarter of the year ending March 31, 2022: Components Business



Billions of yen	FY2021/3 Q1 Actual (A)	FY2022/3 Q1 Actual (B)	Change (B)-(A)
<b>Revenue</b>	<b>4.6</b>	<b>7.7</b>	<b>+3.1</b>
<b>Operating Profit</b>	<b>-0.3</b>	<b>2.1</b>	<b>+2.4</b>
% vs Revenue	-6.5%	27.3%	

## Q1 YoY : Increased revenue and operating profit

- EUV related components business contributed to revenue expansion.
- Sales were strong in optical parts for semiconductor related equipment and encoders for industrial equipment.

Note : In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.

# 1st quarter of the year ending March 31, 2022: Industrial Metrology and Others



Billions of yen	FY2021/3 Q1 Actual (A)	FY2022/3 Q1 Actual (B)	Change (B)-(A)
<b>Revenue</b>	<b>4.9</b>	<b>6.7</b>	<b>+1.8</b>
<b>Operating Profit</b>	<b>0.9</b>	<b>-1.0</b>	<b>-1.9</b>
% vs Revenue	<b>18.4%</b>	<b>-14.9%</b>	

## Q1 YoY : Increased revenue and decreased operating profit

- In the Industrial Metrology Business, revenue expanded by recovering in capex continued in electronic components, semiconductors and automotive-related fields.
- The Others Business recorded a loss due to posting disposals and write-downs of inventory assets at domestic production subsidiaries.

Note : In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.

1. Financial Results for the 1st quarter of the year ending March 31, 2022

2. Forecast for the year ending March 31, 2022

3. Sustainability

# Forecasts for the year ending March 31, 2022



## Revenue

- **Company total forecast : ¥520.0B**  
(Revised upward ¥10.0B vs. previous forecast)
  - **Imaging Products** : Revised upward ¥5.0B reflect to better-than-expected Q1 performance.
  - **Precision Equipment** : Revised upward ¥5.0B reflect to better-than-expected sales for service business in both FPD and semiconductor lithography systems.

## Operating Profit

- **Company total forecast : ¥27.0B**  
(Revised upward ¥7.0B vs. previous forecast)
  - **Imaging Products** : Revised upward ¥7.0B reflect to better-than-expected revenue, improved product mix and higher sales price of products.
  - **Precision Equipment** : Revised upward ¥2.0B by increased revenue of service business etc.
  - **Corporate P/L non-attributable to any reportable segments** : Revised down ¥2.0B due to revision of profit and loss allocation between segments, etc.

## Profit attributable to owners of the parent

- **Company total forecast : ¥22.0B** (Revised upward ¥6.0B vs. previous forecast)

## Shareholder Return

- **Dividend forecast : Annual ¥30, interim: ¥15** (Unchanged from previous forecast)

# Forecast for the year ending March 31, 2022: Financial Highlights



Billions of yen	FY2021/3 Actual (A)	Previous Forecast (May 13) (B)	New Forecast (Aug. 5) (C)	Change (C)-(A)	Change (C)-(B)
<b>Revenue</b>	451.2	<b>510.0</b>	<b>520.0</b>	+68.8	+10.0
<b>Operating Profit</b>	-56.2	<b>20.0</b>	<b>27.0</b>	+83.2	+7.0
% vs Revenue	-12.5%	<b>3.9%</b>	<b>5.2%</b>		
<b>Profit before income taxes</b>	-45.3	<b>22.0</b>	<b>30.0</b>	+75.3	+8.0
% vs Revenue	-10.0%	<b>4.3%</b>	<b>5.8%</b>		
<b>Profit attributable to owners of the parent</b>	-34.4	<b>16.0</b>	<b>22.0</b>	+56.4	+6.0
% vs Revenue	-7.6%	<b>3.1%</b>	<b>4.2%</b>		
<b>EPS</b>	¥-93.96	<b>¥43.57</b>	<b>¥59.91</b>	+¥153.87	+¥16.34
<b>Annual Dividends</b>	¥20	<b>¥30</b>	<b>¥30</b>	+¥10.0	±0
Exchange Rate : US \$	¥106	<b>¥105</b>	<b>¥105</b>	Impact on revenue Approx. +4.9    Approx. +3.8	
EURO	¥124	<b>¥125</b>	<b>¥125</b>	Impact on operating profit Approx. +1.7    Approx. +1.1	

Note: EPS (Basic Earnings per Share) = Profit attributable to owners of the parent / Average number of shares during the term.  
(The actual of FY2021/3 and the forecast of FY2022/3 is calculated by approx. 0.367B shares.)

# Forecast for the year ending March 31, 2022: Financial Highlights by Segment




Billions of yen		FY2021/3 Actual (A)	Previous Forecast (May 13) (B)	New Forecast (Aug. 5) (C)	Change (C)-(A)	Change (C)-(B)
Imaging Products Business	Revenue	150.2	<b>165.0</b>	<b>170.0</b>	+13.2%	+3.0%
	Operating Profit	-36.3 (- 33.0)	<b>5.0</b>	<b>12.0</b>	+¥48.3B	+¥7.0B
	Revenue	184.7	<b>205.0</b>	<b>210.0</b>	+13.7%	+2.4%
Precision Equipment Business	Operating Profit	-0.6 (- 0.6)	<b>17.0</b>	<b>19.0</b>	+¥19.6B	+¥2.0B
	Revenue	62.8	<b>70.0</b>	<b>70.0</b>	+11.5%	±0.0%
Healthcare Business	Operating Profit	-3.0 (- 3.0)	<b>1.0</b>	<b>1.0</b>	+¥4.0B	±¥0B
	Revenue	25.7	<b>35.0</b>	<b>35.0</b>	+36.2%	±0.0%
Components Business	Operating Profit	0.1 (0.1)	<b>8.0</b>	<b>8.0</b>	+¥7.9B	±¥0B
	Revenue	27.6	<b>35.0</b>	<b>35.0</b>	+26.8%	±0.0%
Industrial Metrology and Others	Operating Profit	-1.2 (- 0.3)	<b>3.0</b>	<b>3.0</b>	+¥4.2B	±¥0B
	Revenue	—	—	—	—	—
Corporate P/L non- attributable to any reportable segments	Operating Profit	-15.0 (- 15.0)	<b>-14.0</b>	<b>-16.0</b>	-¥1.0B	-¥2.0B
	Revenue	451.2	<b>510.0</b>	<b>520.0</b>	+15.2%	+2.0%
Consolidated	Operating Profit	-56.2 (- 51.9)	<b>20.0</b>	<b>27.0</b>	+¥83.2B	+¥7.0B

Note: Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

Corporate P/L not attributable to any reportable segments includes the elimination of intersegment transactions that amount to +¥2.5B in FY2021/3.

In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.

# Forecast for the year ending March 31, 2022: Imaging Products Business



## Digital Camera-Interchangeable Lens type (units:1,000)

Market Scale	5,520	5,800	5,800
Nikon	840	750	750

## Interchangeable Lens (units:1,000)

Market Scale	9,110	9,700	9,700
Nikon	1,350	1,300	1,300

## Compact DSC (units:1,000)

Market Scale	3,430	3,200	3,200
Nikon	260	250	250


## • Revenue: Surpassed by ¥19.8B YoY (Surpassed by ¥5.0B vs. previous forecast)

- Digital camera market continues its recovery trend. The market for mid/high end cameras and lenses, particularly focused on, remains strong.
- Continue to launch products for pro/hobbyists.
- Revised revenue upward ¥170.0B for the full year forecast compared to previous forecast, based on Q1 actual.
- Focus on stable supply of parts (including semiconductors) for cameras and lenses.

## • Operating Profit: Surpassed by ¥48.3B YoY (Surpassed by ¥7.0B vs. previous forecast)

- Full-year operating profit is expected to increase by ¥7.0B from previous forecast to ¥12.0B due to higher sales price of products, in addition to a decline in breakeven points by restructuring in the previous year.
- Operating profit for the 2H of the fiscal year will be unchanged from the previous forecast due to deferral of some expenses to the 2H of the fiscal year.

# Forecast for the year ending March 31, 2022: Precision Equipment Business



## FPD Lithography Systems (units)

Market Scale (CY20/21)	52	120	120
Nikon	29	45	45

## Semiconductor Lithography Systems (New/Refurbished, units)

Market Scale (CY20/21)	330	370	370
Nikon	16/11	13/15	13/15

### • Revenue: Up ¥25.3B YoY

**(Surpassed by ¥5.0B vs. previous forecast)**

- FPD: Capex on customers to trend strongly in both large and small and mid-sized panels. Orders are solid, primarily in small and mid-sized panels.
- FPD: 45 systems will be planned to be booked this fiscal year, as installations of systems delayed due to COVID-19 have been progressing. Sales are recorded mainly in the 1H of the fiscal year when sales of systems for large panels are concentrated.
- SPE: Sales of refurbished systems (primarily KrF and i-line) to increase, but new systems will decline due to the period of transitional period in customer capex.
- Both FPD and semiconductor lithography systems continue to operate at high levels on customer site, service revenue such as maintenance are strong.

### • Operating Profit: Up ¥19.6B YoY


**(Surpassed by ¥2.0B vs. previous forecast)**

- Operating profit is expected to increase by ¥2.0B from the previous forecast to ¥19.0B due to strong service-related revenue, etc.
- Most operating profit is expected to be booked in the 1H of the fiscal year.

Note : In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.



# Forecast for the year ending March 31, 2022: Healthcare Business




## • Revenue: Up ¥7.2B YoY

- Increase in sales of biological microscopes due to recovery in the Americas market contributed to increased revenue.
- Retinal diagnostic imaging systems set to post record sales following previous year.
- Start commercial production in the Contract Cell Development and Manufacturing.
- Expect record high sales for the Healthcare Business.

## • Operating Profit: Up ¥4.0B YoY

- Aiming for the first full-year surplus in the Healthcare business, because Q1 actual was going well.

# Forecast for the year ending March 31, 2022: Components Business



- **Revenue: Up ¥9.3B YoY**

- Sales expansion progresses as planned in optical components, optical parts, encoders and FPD photomask substrates, etc.
- EUV related components business progressing well.


- **Operating Profit: Up ¥7.9B YoY**

- In addition to EUV related components, optical components for semiconductor equipment manufacturers and encoders for industrial equipment also contributed to revenue, and steady progress toward full-year operating profit forecast of ¥8.0B.

Note : Actual in FY2021/3 and comments referring previous year are reference, as new disclosure.

In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.

# Forecast for the year ending March 31, 2022: Industrial Metrology and Others



- **Revenue: Up ¥7.4B YoY**

- Continued recovery in capex of electronic components, semiconductors, and automotive fields
- In Industrial Metrology, expand sales in image metrology systems, X-ray inspection systems and non-contact metrology systems, etc.

- **Operating Profit: Up ¥4.2B YoY**

- Aiming to achieve full-year operating profit of ¥3.0B across the segment, including Others in the robust Industrial Metrology Business

Note : In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.

1. Financial Results for the 1st quarter of the year ending March 31, 2022
2. Forecast for the year ending March 31, 2022
3. Sustainability

# Sustainability : Contributing to society through manufacturing with low environmental impact



## 2030 numerical targets

- Reduce emission of greenhouse gases from offices by **70% or more** (compared to FY 2013)
- Shift to renewable energy for **30%** of power used in business activities (become carbon neutral by 2050)

## CSR Priority Issues


1. Creating social value through core technologies

2. Ensuring trustworthiness by maintaining and increasing quality

3. Promoting a decarbonized society

4. Promoting resource circulation

5. Preventing pollution and conserving ecosystems



6. Strengthening supply chain management

7. Respecting human rights

8. Diversity and inclusion

9. Employees' health and safety

10. Thorough compliance

11. Strengthening corporate governance

12. Strengthening risk management

## Major ESG external evaluations

As of August 5, 2021

Member of  
**Dow Jones Sustainability Indices**

Powered by the S&P Global CSA



2021 CONSTITUENT MSCI JAPAN  
ESG SELECT LEADERS INDEX

2021 CONSTITUENT MSCI JAPAN  
EMPOWERING WOMEN INDEX (WIN)



The inclusion of Nikon Corporation in any MSCI index, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement or promotion of Nikon Corporation by MSCI or any of its affiliates. The MSCI indexes are the exclusive property of MSCI. MSCI and the MSCI index names and logos are trademarks or service marks of MSCI or its affiliates.

# Aim for a Sustainable Society : Provide unique Nikon value to society through business



**Innovate the process of manufacturing**

**Contribute to a more comfortable society with imaging and sensing technologies**

**Contribute to peoples' health and quality of life**

**Digital Manufacturing**

**Areas for long-term growth**  
**Vision Systems/Robotics**

**Healthcare**

- Additive processing using optical processing machine. (lightweight and complex shapes)
- Acquired Morf3D Inc. (US) specialized in Contract processing of satellite parts




Image provided by PIXTA

- Riblet processing using optical processing machine (Fluid resistance reduction)
- Fuel efficiency improvements and CO<sub>2</sub> reductions in turbines, wind power, airplanes, etc.
- Signed a joint development agreement with Sharp Corporation related to the implementation of biomimetics technology.



- Coexistence of people and robots - Enhancement of flexibility on manufacturing with Vision System and Robotics
- Optical telecommunications (6G) - Joint validation research with SoftBank Corp
- Provision of remote shooting system that expands the visual world by images from angles that could not be captured in the conventional way (Including collaboration with Mark Roberts Motion Control Limited of subsidiary in UK)



- Life Sciences Solution : Contributions to drug discovery and scientific research
- Eye Care Solution : Contributions to early discovery and treatment of eye diseases
- Contract Cell Development and manufacturing : Develop and manufacture of new drugs for regenerative medicine (CDMO business in subsidiary Nikon CeLL innovation Co., Ltd.)



# Reference Data

# Forecast for the year ending March 31, 2022



	FY2019/3	FY2020/3	FY2021/3			FY2022/3		
	Full year	Full year	1H	2H	Full year	1H	2H	Full year
Billions of yen								
<b>Revenue</b>	708.6	591.0	<b>175.6</b>	<b>275.6</b>	<b>451.2</b>	<b>275.0</b>	<b>245.0</b>	<b>520.0</b>
<b>Operating Profit</b>	82.6	6.7	<b>-46.6</b>	<b>-9.6</b>	<b>-56.2</b>	<b>25.0</b>	<b>2.0</b>	<b>27.0</b>
% vs Revenue	11.7%	1.1%	<b>-26.5%</b>	<b>-3.5%</b>	<b>-12.5%</b>	<b>9.1%</b>	<b>0.8%</b>	<b>5.2%</b>
<b>Profit before income taxes</b>	87.9	11.8	<b>-38.8</b>	<b>-6.5</b>	<b>-45.3</b>	<b>27.0</b>	<b>3.0</b>	<b>30.0</b>
% vs Revenue	12.4%	2.0%	<b>-22.1%</b>	<b>-2.4%</b>	<b>-10.0%</b>	<b>9.8%</b>	<b>1.2%</b>	<b>5.8%</b>
<b>Profit attributable to owners of the parent</b>	66.5	7.6	<b>-31.5</b>	<b>-2.9</b>	<b>-34.4</b>	<b>20.0</b>	<b>2.0</b>	<b>22.0</b>
% vs Revenue	9.4%	1.3%	<b>-17.9%</b>	<b>-1.1%</b>	<b>-7.6%</b>	<b>7.3%</b>	<b>0.8%</b>	<b>4.2%</b>
<b>EPS</b>	¥167.86	¥19.93	<b>-¥93.96</b>			<b>¥59.91</b>		
<b>Annual Dividends</b>	¥60	¥40	<b>¥20</b>			<b>¥30</b>		
<b>ROE</b>	11.2%	1.3%	<b>-6.4%</b>			<b>4.0%</b>		
<b>FCF</b>	43.5	-4.8	<b>22.9</b>			<b>-</b>		
<b>Exchange Rate : US \$</b>	¥111	¥109	<b>¥107</b>	<b>¥105</b>	<b>¥106</b>	<b>¥105</b>		
<b>EURO</b>	¥128	¥121	<b>¥121</b>	<b>¥126</b>	<b>¥124</b>	<b>¥125</b>		



# Financial forecast for the year ending March 31, 2022: by Segments



Billions of yen		FY2019/3	FY2020/3	FY2021/3			FY2022/3		
		Full year	Full year	1H	2H	Full year	1H	2H	Full year
<b>Imaging Products Business</b>	Revenue	296.1	225.8	64.3	85.9	150.2	<b>85.0</b>	<b>85.0</b>	<b>170.0</b>
	Operating Profit	22.0	-17.1	-27.8	-8.5	-36.3	<b>10.0</b>	<b>2.0</b>	<b>12.0</b>
		(22.6)	(- 14.4)	(- 26.7)	(- 6.3)	(- 33.0)			
<b>Precision Equipment Business</b>	Revenue	274.5	245.0	63.8	120.9	184.7	<b>130.0</b>	<b>80.0</b>	<b>210.0</b>
	Operating Profit	81.7	48.0	-7.4	6.8	-0.6	<b>18.0</b>	<b>1.0</b>	<b>19.0</b>
		(81.7)	(48.0)	(- 7.4)	(6.8)	(- 0.6)			
<b>Healthcare Business</b>	Revenue	65.4	62.0	25.7	37.1	62.8	<b>30.0</b>	<b>40.0</b>	<b>70.0</b>
	Operating Profit	-1.9	-2.4	-2.3	-0.7	-3.0	<b>0.0</b>	<b>1.0</b>	<b>1.0</b>
		(- 1.9)	(- 2.4)	(- 2.3)	(- 0.7)	(- 3.0)			
<b>Components Business</b>	Revenue	-	-	10.4	15.3	25.7	<b>15.0</b>	<b>20.0</b>	<b>35.0</b>
	Operating Profit	-	-	-0.9	1.0	0.1	<b>3.0</b>	<b>5.0</b>	<b>8.0</b>
		-	-	(- 0.9)	(1.0)	(0.1)			
<b>Industrial Metrology and Others</b>	Revenue	72.5	58.0	11.2	16.4	27.6	<b>15.0</b>	<b>20.0</b>	<b>35.0</b>
	Operating Profit	6.9	1.8	-0.5	-0.7	-1.2	<b>0.0</b>	<b>3.0</b>	<b>3.0</b>
		(7.5)	(1.8)	(- 0.4)	(0.1)	(- 0.3)			
<b>Corporate P/L non-attributable to any reportable segments</b>	Revenue	-	-	-	-	-	<b>-</b>	<b>-</b>	<b>-</b>
	Operating Profit	-26.1	-23.6	-7.4	-7.6	-15	<b>-6.0</b>	<b>-10.0</b>	<b>-16.0</b>
		(- 25.6)	(- 21.9)	(- 7.4)	(- 7.6)	(- 15.0)			
<b>Consolidated</b>	Revenue	708.6	591.0	175.6	275.6	451.2	<b>275.0</b>	<b>245.0</b>	<b>520.0</b>
	Operating Profit	82.6	6.7	-46.6	-9.6	-56.2	<b>25.0</b>	<b>2.0</b>	<b>27.0</b>
		(84.4)	(11.2)	(- 45.3)	(- 6.6)	(- 51.9)			

Note: Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.

# Actual for the year ended March 31, 2022:by Segments



Billions of yen		FY2021/3				FY2022/3
		Q1	Q2	Q3	Q4	Q1
Imaging Products Business	Revenue	25.1	39.2	52.4	33.5	50.0
	Operating Profit	-8.3 (- 8.0)	-19.5 (- 18.7)	-0.8 (- 0.2)	-7.7 (- 6.1)	9.2
Precision Equipment Business	Revenue	19.6	44.2	66.6	54.3	51.8
	Operating Profit	-5.7 (- 5.7)	-1.7 (- 1.7)	11.4 (11.4)	-4.6 (- 4.6)	10.6
Healthcare Business	Revenue	10.3	15.4	17.1	20.0	15.8
	Operating Profit	-2.4 (- 2.4)	0.1 (0.1)	0.7 (0.7)	-1.4 (- 1.4)	0.4
Components Business	Revenue	4.6	5.8	7.7	7.6	7.7
	Operating Profit	-0.3 (- 0.3)	-0.6 (- 0.6)	1.2 (1.2)	-0.2 (- 0.2)	2.1
Industrial Metrology and Others	Revenue	4.9	6.3	6.9	9.5	6.7
	Operating Profit	0.9 (0.9)	-1.4 (- 1.3)	0.5 (0.6)	-1.2 (- 0.5)	-1.0
Corporate P/L non-attributable to any reportable segments	Revenue	—	—	—	—	—
	Operating Profit	-4.6 (- 4.6)	-2.8 (- 2.8)	-3.5 (- 3.5)	-4.1 (- 4.1)	-1.5
Consolidated	Revenue	64.7	110.9	150.6	125.0	132.2
	Operating Profit	-20.5 (- 20.2)	-26.1 (- 25.1)	9.9 (10.5)	-19.5 (- 17.1)	19.9


Note: Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

In April 2021, some production subsidiaries related to the Imaging Products Business, Precision Equipment Business, and Components Business were transferred to Industrial Metrology and Others, and retroactively applied to the FY2021/3.


# 1st quarter of the year ending March 31, 2022: Financial Position Breakdown



## ASSETS



## LIABILITIES/ EQUITY




Note: Equity ratio is ratio of equity attributable to owners of the parent to total assets. Cash and Cash Equivalents excludes time deposits with maturities of three months or more.


# Capital Expenditures, Depreciation and Inventory



## CAPITAL EXPENDITURES, DEPRECIATION



## INVENTORY BREAKDOWN



Note: Capital expenditures in FY2020/3 and beyond include the leased assets upon the adoption of IFRS16.

Depreciation from FY2018/3 includes the amortization of capitalized R&D costs and from FY2020/3 includes leased assets, same as capital expenditures.


The Semiconductor Related Equipment Business, which had belonged to Industrial Metrology and Others, has been transferred to the Precision Equipment Business.

Inventory of ¥2.6B in the end of FY2020/3 have been transferred from Industrial Metrology and Others to the Precision Equipment Business as a result of retroactive application to the end of FY2020/3 respectively.


# 1st quarter of the year ending March 31, 2022: Revenue Breakdown



## BY SEGMENT



## BY REGION




Note: The outside and inside circles show the breakdown of FY2022/3 revenue of ¥132.2B and FY2021/3 revenue of ¥64.7B, respectively.


# Forecast for the year ending March 31, 2022: R&D Expenditures



## R&D EXPENDITURES




## R&D EXPENDITURES BREAKDOWN



Note: R&D expenditures after FY2018/3 includes capitalization of some development expenditure.

# Cash Flow History




Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents

# Imaging Products Business: Sales Units



## SALES IN UNITS BY PRODUCT CATEGORY







# Forecast for the year ending March 31, 2022: Precision Equipment Business Sales Units



## FPD LITHOGRAPHY SYSTEMS SALES BY GENERATION




## SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)




Note: The unit sales of new semiconductor lithography systems is 17 units in FY2018/3, 21 units in FY2019/3, 34 units in FY2020/3, 16 units in FY2021/3 and 13 units (forecast) in FY2022/3.

## FPD LITHOGRAPHY SYSTEMS SALES IN UNITS BY GENERATION



**SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES  
IN UNITS BY TECHNOLOGY (INCL. REFURBISHED)**



# Forecast for the year ending March 31, 2022: Foreign Exchange Impact



	Exchange Rate	Financial Impact from Fluctuation by 1 yen	
	FY2022/3 Forecast for Q2~Q4	Revenue Q2~Q4	Operating Profit Q2~Q4
US \$	¥ 105	Approx. ¥ 1.4B	Approx. ¥ 0.2B
EURO	¥ 125	Approx. ¥ 0.4B	Approx. ¥ 0.2B

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US \$ and EURO.

# Disclaimer Regarding Forecast and Projections

---



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

